

# Thrombopoietin Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

<https://marketpublishers.com/r/T614E45FDA86EN.html>

Date: September 2025

Pages: 76

Price: US\$ 3,200.00 (Single User License)

ID: T614E45FDA86EN

## Abstracts

### Thrombopoietin Receptor Agonist Market Summary

The thrombopoietin receptor agonist (TPO-RA) market is a specialized niche within hematology therapeutics, focusing on synthetic mimics of thrombopoietin that stimulate megakaryocyte proliferation and platelet production to address thrombocytopenia, a condition characterized by low platelet counts below 150,000 per microliter, increasing bleeding risks in immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia (CIT), and chronic liver disease (CLD)-associated cases. TPO-RAs represent a paradigm shift from platelet transfusions and corticosteroids, offering oral or injectable options that elevate platelet levels by 50,000-100,000 per microliter within weeks, reducing hemorrhage events by up to 60% in clinical settings. Market features encompass second-generation agents with improved bioavailability and reduced off-target effects compared to first-generation peptides, emphasizing once-daily dosing for chronic ITP and short-course regimens for periprocedural bleeding in CLD patients. Precision hematology drives adoption, with algorithms incorporating bone marrow biopsies and anti-TPO antibody screening to select responders, while real-world registries highlight sustained responses beyond 24 months in 70% of users. The sector grapples with monitoring for thrombocytosis and rare marrow fibrosis, alongside high costs prompting payer restrictions, yet orphan drug statuses incentivize expansions into aplastic anemia and myelodysplastic syndromes. Innovation pivots to next-generation small molecules with pan-agonist activity and gene therapies enhancing endogenous TPO signaling, supported by FDA fast-track designations for refractory subsets. By 2025, the global TPO-RA market is estimated to be valued between USD 3.2 billion and USD 4.2 billion, with a projected compound annual growth rate (CAGR) of 1% to 3% through 2030. This subdued growth trajectory underscores biosimilar entries post-patent

expiry, steady ITP prevalence amid aging populations, and guideline endorsements for frontline use in adult refractory cases, moderated by generic erosion and stagnant CIT indications.

## Regional Market Trends

The TPO-RA market manifests region-specific trajectories, influenced by thrombocytopenia epidemiology, transfusion infrastructures, and pharmacoeconomic evaluations.

**North America:** Exhibiting a CAGR of 0.5%–2.5%, the United States dominates consumption through high ITP diagnosis rates via automated complete blood counts in routine checkups, with trends toward subcutaneous shifts for home administration in urban oncology networks like those in Texas and New York.

**Europe:** Projected at a CAGR of 0.5%–2.0%, Germany and the United Kingdom lead via EMA harmonized labels and national formularies prioritizing cost-utility thresholds, emphasizing oral formulations in liver clinics to curb procedural delays.

**Asia-Pacific:** Growing at a CAGR of 1.5%–3.5%, Japan and China propel uptake amid hepatitis B-linked CLD burdens, supported by national reimbursement lists for perisurgical prophylaxis in high-volume transplant centers.

**Latin America:** At a CAGR of 1.0%–3.0%, Brazil and Mexico advance through PAHO initiatives targeting chemotherapy patients, with focus on affordable generics addressing rural access voids.

**Middle East and Africa (MEA):** With a CAGR of 0.5%–2.5%, Saudi Arabia drives momentum via Gulf-funded hematology hubs, though African ITP underreporting constrains scale despite WHO-backed screening in malaria-endemic zones.

## Application Analysis

The TPO-RA market centers on thrombocytopenia applications, stratified by etiology with evolutions toward multimodal integration and expanded perioperative roles.

**Immune Thrombocytopenia (ITP):** This primary application utilizes chronic TPO-RA therapy to maintain platelets above 50,000 per microliter in adults failing steroids, achieving 80% response rates; trends include pediatric extensions and combination with rituximab for steroid-sparing, per ASH 2025 guidelines emphasizing early initiation post-three-month inefficacy.

**Chemotherapy-Induced Thrombocytopenia (CIT):** Short-term dosing supports dose-dense regimens in solid tumors, reducing delays by 40%; developments highlight predictive nomograms incorporating baseline counts, positioning TPO-RAs as adjuncts to carboplatin in ovarian cancer protocols.

**Chronic Liver Disease-Associated Thrombocytopenia (CLD-TP):** Pre-procedural boosts enable biopsies and ablations, with 70% achieving >50,000 platelets; current trajectories involve lusutrombopag's five-day courses and real-world data on portal hypertension cohorts, fostering label broadenings to variceal bleeding prophylaxis.

## Company Profiles

**Novartis:** Novartis's Promacta/Revolade (eltrombopag), an oral non-peptide TPO-RA, generated USD 2.2 billion in 2024 product sales, reflecting a 2% decline amid U.S. generic competition post-patent expiry, while European exclusivity persists until 2025; integrated into Novartis's hematology portfolio, it contributed to total 2024 net sales growth, with Q4 2024 at USD 583 million despite promotional discontinuations in select markets.

**Amgen:** Amgen's Nplate (romiplostim), a weekly subcutaneous peptide mimetic, posted USD 1.2-1.8 billion in 2024 revenues, with Q4 at USD 337 million down 13% year-over-year due to U.S. government stocking normalization, yet Q3 surged to USD 456 million on oncology demand; patents hold until 2027-2028 in key markets, bolstering Amgen's 2024 total revenues of USD 33.4 billion, up 19%.

**Sobi:** Sobi's Doptelet (avatrombopag), an oral TPO-RA for CLD-TP and ITP, achieved SEK 1.1 billion (approximately USD 100 million) in Q4 2024 revenues, up significantly from prior year, contributing to full-year specialty care growth within SEK 26 billion total; expansions into pediatric ITP underscore its niche in rare hematology.

Edding Group: Edding Group's Mulpleta (lusutrombopag), a short-course oral agent for CLD-TP, maintains steady demand in Asia-Pacific perisurgical markets following 2023 approvals, aligning with Edding's focus on innovative hematology imports, though specific 2024 revenues remain modest amid competitive launches.

### Industry Value Chain Analysis

The TPO-RA value chain interlinks recombinant protein engineering with precision hematology delivery, reflecting chronic management imperatives and biosimilar scalability. It commences with R&D, deploying JAK2-STAT5 signaling assays and xenotransplant models to optimize receptor affinity, progressing through Phase III non-inferiority trials against transfusions with bleeding event endpoints, often leveraging FDA orphan incentives for six-month exclusivities. Manufacturing splits: peptide-based like romiplostim via *E. coli* expression with PEGylation for half-life extension, ensuring

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

### **CHAPTER 2 ABBREVIATION AND ACRONYMS**

### **CHAPTER 3 PREFACE**

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

### **CHAPTER 5 MARKET TREND ANALYSIS**

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

### **CHAPTER 6 INDUSTRY CHAIN ANALYSIS**

6.1 Upstream/Suppliers Analysis

6.2 Thrombopoietin Receptor Agonist Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

### **CHAPTER 7 LATEST MARKET DYNAMICS**

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

## **CHAPTER 8 HISTORICAL AND FORECAST THROMBOPOIETIN RECEPTOR AGONIST MARKET IN NORTH AMERICA (2020-2030)**

- 8.1 Thrombopoietin Receptor Agonist Market Size
- 8.2 Thrombopoietin Receptor Agonist Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Thrombopoietin Receptor Agonist Market Size by Type
- 8.5 Key Countries Analysis
  - 8.5.1 United States
  - 8.5.2 Canada

## **CHAPTER 9 HISTORICAL AND FORECAST THROMBOPOIETIN RECEPTOR AGONIST MARKET IN SOUTH AMERICA (2020-2030)**

- 9.1 Thrombopoietin Receptor Agonist Market Size
- 9.2 Thrombopoietin Receptor Agonist Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Thrombopoietin Receptor Agonist Market Size by Type
- 9.5 Key Countries Analysis

## **CHAPTER 10 HISTORICAL AND FORECAST THROMBOPOIETIN RECEPTOR AGONIST MARKET IN ASIA & PACIFIC (2020-2030)**

- 10.1 Thrombopoietin Receptor Agonist Market Size
- 10.2 Thrombopoietin Receptor Agonist Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Thrombopoietin Receptor Agonist Market Size by Type
- 10.5 Key Countries Analysis
  - 10.5.1 China
  - 10.5.2 India
  - 10.5.3 Japan
  - 10.5.4 South Korea
  - 10.5.5 Southeast Asia
  - 10.5.6 Australia

## **CHAPTER 11 HISTORICAL AND FORECAST THROMBOPOIETIN RECEPTOR**

## **AGONIST MARKET IN EUROPE (2020-2030)**

- 11.1 Thrombopoietin Receptor Agonist Market Size
- 11.2 Thrombopoietin Receptor Agonist Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Thrombopoietin Receptor Agonist Market Size by Type
- 11.5 Key Countries Analysis
  - 11.5.1 Germany
  - 11.5.2 France
  - 11.5.3 United Kingdom
  - 11.5.4 Italy
  - 11.5.5 Spain
  - 11.5.6 Belgium
  - 11.5.7 Netherlands
  - 11.5.8 Austria
  - 11.5.9 Poland
  - 11.5.10 Russia

## **CHAPTER 12 HISTORICAL AND FORECAST THROMBOPOIETIN RECEPTOR AGONIST MARKET IN MEA (2020-2030)**

- 12.1 Thrombopoietin Receptor Agonist Market Size
- 12.2 Thrombopoietin Receptor Agonist Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Thrombopoietin Receptor Agonist Market Size by Type
- 12.5 Key Countries Analysis

## **CHAPTER 13 SUMMARY FOR GLOBAL THROMBOPOIETIN RECEPTOR AGONIST MARKET (2020-2025)**

- 13.1 Thrombopoietin Receptor Agonist Market Size
- 13.2 Thrombopoietin Receptor Agonist Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Thrombopoietin Receptor Agonist Market Size by Type

## **CHAPTER 14 GLOBAL THROMBOPOIETIN RECEPTOR AGONIST MARKET FORECAST (2025-2030)**

- 14.1 Thrombopoietin Receptor Agonist Market Size Forecast

14.2 Thrombopoietin Receptor Agonist Application Forecast

14.3 Competition by Players/Suppliers

14.4 Thrombopoietin Receptor Agonist Type Forecast

## **CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS**

15.1 Novartis

15.1.1 Company Profile

15.1.2 Main Business and Thrombopoietin Receptor Agonist Information

15.1.3 SWOT Analysis of Novartis

15.1.4 Novartis Thrombopoietin Receptor Agonist Revenue, Gross Margin and Market Share (2020-2025)

15.2 Amgen

15.2.1 Company Profile

15.2.2 Main Business and Thrombopoietin Receptor Agonist Information

15.2.3 SWOT Analysis of Amgen

15.2.4 Amgen Thrombopoietin Receptor Agonist Revenue, Gross Margin and Market Share (2020-2025)

15.3 Sobi

15.3.1 Company Profile

15.3.2 Main Business and Thrombopoietin Receptor Agonist Information

15.3.3 SWOT Analysis of Sobi

15.3.4 Sobi Thrombopoietin Receptor Agonist Revenue, Gross Margin and Market Share (2020-2025)

15.4 Edding Group

15.4.1 Company Profile

15.4.2 Main Business and Thrombopoietin Receptor Agonist Information

15.4.3 SWOT Analysis of Edding Group

15.4.4 Edding Group Thrombopoietin Receptor Agonist Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

## Tables & Figures

### TABLES AND FIGURES

Table Abbreviation and Acronyms

Table Research Scope of Thrombopoietin Receptor Agonist Report

Table Data Sources of Thrombopoietin Receptor Agonist Report

Table Major Assumptions of Thrombopoietin Receptor Agonist Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Thrombopoietin Receptor Agonist Picture

Table Thrombopoietin Receptor Agonist Classification

Table Thrombopoietin Receptor Agonist Applications

Table Drivers of Thrombopoietin Receptor Agonist Market

Table Restraints of Thrombopoietin Receptor Agonist Market

Table Opportunities of Thrombopoietin Receptor Agonist Market

Table Threats of Thrombopoietin Receptor Agonist Market

Table COVID-19 Impact for Thrombopoietin Receptor Agonist Market

Table Raw Materials Suppliers

Table Different Production Methods of Thrombopoietin Receptor Agonist

Table Cost Structure Analysis of Thrombopoietin Receptor Agonist

Table Key End Users

Table Latest News of Thrombopoietin Receptor Agonist Market

Table Merger and Acquisition

Table Planned/Future Project of Thrombopoietin Receptor Agonist Market

Table Policy of Thrombopoietin Receptor Agonist Market

Table 2020-2030 North America Thrombopoietin Receptor Agonist Market Size

Figure 2020-2030 North America Thrombopoietin Receptor Agonist Market Size and CAGR

Table 2020-2030 North America Thrombopoietin Receptor Agonist Market Size by Application

Table 2020-2025 North America Thrombopoietin Receptor Agonist Key Players Revenue

Table 2020-2025 North America Thrombopoietin Receptor Agonist Key Players Market Share

Table 2020-2030 North America Thrombopoietin Receptor Agonist Market Size by Type

Table 2020-2030 United States Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Canada Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 South America Thrombopoietin Receptor Agonist Market Size

Figure 2020-2030 South America Thrombopoietin Receptor Agonist Market Size and CAGR

Table 2020-2030 South America Thrombopoietin Receptor Agonist Market Size by Application

Table 2020-2025 South America Thrombopoietin Receptor Agonist Key Players Revenue

Table 2020-2025 South America Thrombopoietin Receptor Agonist Key Players Market Share

Table 2020-2030 South America Thrombopoietin Receptor Agonist Market Size by Type

Table 2020-2030 Asia & Pacific Thrombopoietin Receptor Agonist Market Size

Figure 2020-2030 Asia & Pacific Thrombopoietin Receptor Agonist Market Size and CAGR

Table 2020-2030 Asia & Pacific Thrombopoietin Receptor Agonist Market Size by Application

Table 2020-2025 Asia & Pacific Thrombopoietin Receptor Agonist Key Players Revenue

Table 2020-2025 Asia & Pacific Thrombopoietin Receptor Agonist Key Players Market Share

Table 2020-2030 Asia & Pacific Thrombopoietin Receptor Agonist Market Size by Type

Table 2020-2030 China Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 India Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Japan Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 South Korea Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Southeast Asia Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Australia Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Europe Thrombopoietin Receptor Agonist Market Size

Figure 2020-2030 Europe Thrombopoietin Receptor Agonist Market Size and CAGR

Table 2020-2030 Europe Thrombopoietin Receptor Agonist Market Size by Application

Table 2020-2025 Europe Thrombopoietin Receptor Agonist Key Players Revenue

Table 2020-2025 Europe Thrombopoietin Receptor Agonist Key Players Market Share

Table 2020-2030 Europe Thrombopoietin Receptor Agonist Market Size by Type

Table 2020-2030 Germany Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 France Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 United Kingdom Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Italy Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Spain Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Belgium Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Netherlands Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Austria Thrombopoietin Receptor Agonist Market Size

Table 2020-2030 Poland Thrombopoietin Receptor Agonist Market Size  
Table 2020-2030 Russia Thrombopoietin Receptor Agonist Market Size  
Table 2020-2030 MEA Thrombopoietin Receptor Agonist Market Size  
Figure 2020-2030 MEA Thrombopoietin Receptor Agonist Market Size and CAGR  
Table 2020-2030 MEA Thrombopoietin Receptor Agonist Market Size by Application  
Table 2020-2025 MEA Thrombopoietin Receptor Agonist Key Players Revenue  
Table 2020-2025 MEA Thrombopoietin Receptor Agonist Key Players Market Share  
Table 2020-2030 MEA Thrombopoietin Receptor Agonist Market Size by Type  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Size by Region  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Size Share by Region  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Size by Application  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Share by Application  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Key Vendors Revenue  
Figure 2020-2025 Global Thrombopoietin Receptor Agonist Market Size and Growth Rate  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Key Vendors Market Share  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Size by Type  
Table 2020-2025 Global Thrombopoietin Receptor Agonist Market Share by Type  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Market Size by Region  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Market Size Share by Region  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Market Size by Application  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Market Share by Application  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Key Vendors Revenue  
Figure 2025-2030 Global Thrombopoietin Receptor Agonist Market Size and Growth Rate  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Key Vendors Market Share  
Table 2025-2030 Global Thrombopoietin Receptor Agonist Market Size by Type  
Table 2025-2030 Thrombopoietin Receptor Agonist Global Market Share by Type  
Table Novartis Information  
Table SWOT Analysis of Novartis  
Table 2020-2025 Novartis Thrombopoietin Receptor Agonist Revenue Gross Profit Margin  
Figure 2020-2025 Novartis Thrombopoietin Receptor Agonist Revenue and Growth Rate  
Figure 2020-2025 Novartis Thrombopoietin Receptor Agonist Market Share  
Table Amgen Information  
Table SWOT Analysis of Amgen

Table 2020-2025 Amgen Thrombopoietin Receptor Agonist Revenue Gross Profit Margin

Figure 2020-2025 Amgen Thrombopoietin Receptor Agonist Revenue and Growth Rate

Figure 2020-2025 Amgen Thrombopoietin Receptor Agonist Market Share

Table Sobi Information

Table SWOT Analysis of Sobi

Table 2020-2025 Sobi Thrombopoietin Receptor Agonist Revenue Gross Profit Margin

Figure 2020-2025 Sobi Thrombopoietin Receptor Agonist Revenue and Growth Rate

Figure 2020-2025 Sobi Thrombopoietin Receptor Agonist Market Share

Table Edding Group Information

Table SWOT Analysis of Edding Group

Table 2020-2025 Edding Group Thrombopoietin Receptor Agonist Revenue Gross Profit Margin

Figure 2020-2025 Edding Group Thrombopoietin Receptor Agonist Revenue and Growth Rate

Figure 2020-2025 Edding Group Thrombopoietin Receptor Agonist Market Share

.....

## I would like to order

Product name: Thrombopoietin Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

Product link: <https://marketpublishers.com/r/T614E45FDA86EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T614E45FDA86EN.html>